Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Post-transplantation lymphoproliferative disease

This disease is a lymphoid proliferation or a lymphoma that develops as a consequence of immunosuppression in a patient transplanted with a solid organ or bone marrow. The histology is characterized by a proliferation of polymorphic B-cells (such as immunoblasts, plasma blasts and plasma cells). Post-transplantation lymphomas can also be monomorphic and are then classified as equivalent lymphoma (Burkitt's lymphoma, plasma cell myeloma etc.) in the WHO classification.

Post-transplantation lymphoproliferative disease (polymorphic) is often monoclonal and Epstein-Barr virus-mediated. Extra nodal manifestations occur frequently.

EBV-positive lesions occur months to years after the transplantation. Histological examinations show many variants.

The condition is fatal in about 60% of patients.

EBV-positive lesions occurring early may spontaneously disappear by reducing the intensity of the immunosuppressive treatment. If there is no response, treatment for polymorphic subtypes is rituximab monotherapy. For more well-defined lymphoma types, such as DLBCL, treatment in addition to modifying the immunosuppressive therapy should consist of CHOP-based therapy with rituximab, according to regular guidelines.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017